Bristol Myers Squibb Co SEC filings CELG-RI
Bristol Myers Squibb Co has 1,003 filings in SEC EDGAR's recent list, going back to Apr 2, 2019. Its latest annual report, Form ARS, was filed on Mar 25, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 29, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (results of operations, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 17, 2026 | — |
| DEFA14A | Additional proxy material | Mar 25, 2026 | — |
| DEF 14A | Proxy statement | Mar 25, 2026 | May 5, 2026 |
| DEFA14A | Additional proxy material | Apr 15, 2025 | — |
| DEFA14A | Additional proxy material | Mar 26, 2025 | — |
| DEF 14A | Proxy statement | Mar 26, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 22, 2024 | — |
| DEFA14A | Additional proxy material | Mar 28, 2024 | — |
| DEF 14A | Proxy statement | Mar 28, 2024 | May 7, 2024 |
| PRE 14A | Preliminary proxy statement | Mar 18, 2024 | May 7, 2024 |
| DEFA14A | Additional proxy material | Apr 26, 2023 | — |
| DEFA14A | Additional proxy material | Apr 10, 2023 | — |
| DEFA14A | Additional proxy material | Mar 23, 2023 | — |
| DEF 14A | Proxy statement | Mar 23, 2023 | — |
| DEFA14A | Additional proxy material | Apr 20, 2022 | — |
| DEFA14A | Additional proxy material | Mar 24, 2022 | — |
| DEF 14A | Proxy statement | Mar 24, 2022 | May 3, 2022 |
| DEFA14A | Additional proxy material | Apr 19, 2021 | — |
| DEFA14A | Additional proxy material | Mar 25, 2021 | — |
| DEF 14A | Proxy statement | Mar 25, 2021 | May 4, 2021 |
| PRE 14A | Preliminary proxy statement | Mar 12, 2021 | May 4, 2021 |
| DEFA14A | Additional proxy material | Apr 23, 2020 | — |
| DEFA14A | Additional proxy material | Apr 14, 2020 | — |
| DEFA14A | Additional proxy material | Mar 25, 2020 | — |
| DEF 14A | Proxy statement | Mar 25, 2020 | May 5, 2020 |
| DEF 14A | Proxy statement | Apr 30, 2019 | May 29, 2019 |
Showing 26 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BMY (NYSE), CELG-RI (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 14272
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.